IBA

Based in Louvain-la-Neuve, Belgium, and founded by Yves Jongen (CRO) in 1986, IBA (Ion Beam Applications) operates as a developer and manufacturer of medical devices and software solutions for cancer treatment. The company is trading under Brussels Stock Exchange under the ticker symbol IBAB. In May 1993, the firm raised an investment led by SRIW. The firm as of April 2023, has 4 business units with a presence in over 40 countries and offices in Belgium, China, Germany, the US, and Russia, and is led by its CEO, Olivier Legrain.

The global medical solutions company through partnership, assists cancer clinics and academic health centers, with a fully integrated approach to patient flow. The company’s core products include proton therapy, dosimetry and quality assurance, radiopharma solutions, and industrial solutions. Proton Therapy is a form of radiation therapy that targets cancer cells while minimizing damage to surrounding healthy tissue. Dosimetry and Quality Assurance is a quality control system that ensures the accuracy of radiation therapy delivery.

Radiopharma solutions are used in nuclear medicine to diagnose and treat diseases. Industrial solutions are used for materials science and non-destructive testing. The other solution offered by IBA is a proton therapy community platform to create profiles and discover campus, myQA SRS to maximize accuracy and efficiency for SIMT (single-isocenter multitarget) radiosurgery plans, Matrixx Resolution to offer high resolution for IMRT (intensity-modulated radiation therapy) and VMAT (volumetric modulated arc therapy) patient QA (quality assurance), and BEYOND™ for end-to-end irradiation solutions powered by the Rhodotron. The company also offers business plans, financing, building, installation, training, and commissioning solutions to its partners.